Showing results (151-160 of 164) with videos related to
Sort By:
Pageof 17
Proceedings of the National Academy of Sciences of the United States of America|April 19, 2023
Fragmentation landscape of cell-free DNA revealed by deconvolutional analysis of end motifsZe Zhou, Mary-Jane L Ma, Rebecca W Y Chan, et al.Hepatology (Baltimore, Md.)|November 8, 2019
Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response-Based ApproachGuohong Han, Sarah Berhane, Hidenori Toyoda, et al.Journal of Experimental & Clinical Cancer Research : CR|June 2, 2022
A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumorsStephen L Chan, Martin Schuler, Yoon-Koo Kang, et al.Med (New York, N.Y.)|April 10, 2025
Chromatin accessibility states affect transrenal clearance of plasma DNA: Implications for urine-based diagnosticsMary-Jane L Ma, Woody Z Zhang, Peiyong Jiang, et al.Cancer Discovery|October 3, 2019
First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular CarcinomaRichard D Kim, Debashis Sarker, Tim Meyer, et al.Hepatology International|November 21, 2024
APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024George Lau, Shuntaro Obi, Jian Zhou, et al.European Journal of Cancer (Oxford, England : 1990)|July 13, 2024
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide populationMargherita Rimini, Lorenzo Fornaro, Mario Domenico Rizzato, et al.The Oncologist|October 19, 2024
Efficacy of cisplatin-gemcitabine-durvalumab in patients with advanced biliary tract cancer experiencing early vs late disease relapse after surgery: a large real-life worldwide populationFederica Lo Prinzi, Francesca Salani, Margherita Rimini, et al.Targeted Oncology|February 27, 2026
Prognostic Impact of Metastatic Sites in Patients with Biliary Tract Cancer Treated with Cisplatin, Gemcitabine, and DurvalumabSilvia Camera, Lorenzo Fornaro, Margherita Rimini, et al.International Journal of Cancer|May 19, 2025
Factors associated with reaching maintenance therapy in patients with advanced biliary tract cancer treated with durvalumab: Real-world results from a multicenter and multinational studyMargherita Rimini, Lorenzo Fornaro, Federica Lo Prinzi, et al.Pageof 17